Safety Study Extension of Iloprost Power 15 in Pulmonary Arterial Hypertension

You may be eligible if

• 1. Signed informed consent prior to initiation of any study mandated procedure,
• 2. Patients with symptomatic idiopathic or familial pulmonary arterial hypertension in NYHA functional class II to IV who have completed study AC-063A301,
• 3. Women of childbearing potential must have a negative urine pregnancy test and must use an adequate method of contraception during the study and for 28 days after discontinuation of the study drug.
• 2. Pulmonary arterial hypertension associated with significant venous or capillary involvement (Pulmonary capillary wedge pressure (PCWP) \> 15 mmHg), known pulmonary veno-occlusive disease, or pulmonary capillary hemangiomatosis,
• 3. Moderate to severe obstructive lung disease: forced expiratory volume in 1 second/forced vital capacity (FEV1/FVC) \< 70% and FEV1 \< 65% of predicted value after bronchodilator administration,
• 4. Moderate to severe restrictive lung disease: total lung capacity (TLC) \< 60% of predicted value,
• 5. Pregnant or breast-feeding women,
• 6. Systemic hypertension (systolic blood pressure \> 160 mmHg or diastolic blood pressure \> 100 mmHg on repeated measurement),
• 7. Systolic blood pressure \< 95 mmHg,
• 8. Moderate to severe hepatic impairment, i.e., Child-Pugh Class B or C,
• 9. Chronic renal insufficiency defined by serum creatinine \> 2.5 mg/dL (221 μmol/L) or ongoing dialysis,
• 10. Clinically relevant bleeding disorder or active bleeding,
• 11. Known hypersensitivity to iloprost or any of its excipients.